R1 Therapeutics: Funding, Investors & Team (Oct 2026)
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals with chronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease.
R1 Therapeutics has raised $80.5M across 2 funding rounds on record, the most recent a Series A of $3.0M announced in Sep 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
R1 Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2026.
R1 Therapeutics Funding Rounds
R1 Therapeutics raised $77.5M in a Series A announced in Mar 2026.
6 months later, a Series A of $3.0M was announced in Sep 2026.
R1 Therapeutics Investors
7 investors are recorded in total; the 5 named above are those the record identifies.
R1 Therapeutics Founders and Leadership Team
Contact details for the R1 Therapeutics team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →R1 Therapeutics Funding Compared to Other Biotechnology Startups
R1 Therapeutics' latest round of $3.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like R1 Therapeutics in Biotechnology and London
Companies Similar to R1 Therapeutics
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
R1 Therapeutics Funding FAQs
What does R1 Therapeutics do?
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals with chronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease.
How much funding has R1 Therapeutics raised?
R1 Therapeutics has raised $80.5M across 2 rounds on record. The most recent is a Series A of $3.0M announced in Sep 2026.
When did R1 Therapeutics last raise funding?
R1 Therapeutics' most recent funding round on record is a Series A of $3.0M, announced in Sep 2026.
Who has invested in R1 Therapeutics?
Investors on record for R1 Therapeutics include Samsara BioCapital, Curie.Bio, Abingworth, U.S. Renal Care, F-Prime. FundedIQ records 7 investors in total.
Who founded R1 Therapeutics?
FundedIQ lists Krishna Polu (Founder) at R1 Therapeutics.
Where is R1 Therapeutics headquartered?
R1 Therapeutics is based in London, England, United Kingdom.
How many employees does R1 Therapeutics have?
R1 Therapeutics is in the 1-10 employee band.
When was R1 Therapeutics founded?
R1 Therapeutics was founded in 2026.
How does R1 Therapeutics' funding compare to other Biotechnology startups?
R1 Therapeutics' latest round of $3.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's R1 Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for R1 Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.